Quantcast

Latest Pramipexole Stories

2011-03-24 14:54:42

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients. Mayo Clinic first reported on this topic in 2005. The follow-up study was published online in the February 2011 issue of Parkinsonism and Related Disorders. Dopamine agonists, a class of drugs that include pramipexole (Mirapex) and ropinirole (Requip), are commonly used to treat Parkinson's disease. The drugs stimulate the brain's...

2010-12-07 12:56:01

A drug prescribed for Parkinson's disease may also treat restless leg syndrome without the adverse side effects of current therapies, Medical College of Georgia researchers say. Rasagaline works by prolonging the effect of dopamine, a chemical that transmits signals between nerve cells in the brain. The cause of RLS is unknown, but research suggests a dopamine imbalance. Parkinson's is caused by a dopamine insufficiency. "The hope is that Rasagaline, because it prolongs the effect of existing...

2010-11-30 07:00:00

BURLINGTON, Mass., Nov. 30, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when comparing dopamine agonist use for Parkinson's disease, more frequent use of once-daily formulations of Requip (GlaxoSmithKline's Requip, Requip XL/LP/Modutab/RP/Prolib) and Mirapex (Boehringer Ingelheim's Mirapex/Sifrol/Mirapexin; Mirapex ER/Mirapexin ER/Sifrol Retard) occurs in France than in the remaining...

2010-10-19 11:26:00

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online...

2010-10-15 16:36:17

Participants with fibromyalgia were 11 times more likely to have RLS than healthy controls A study in the Oct. 15 issue of the Journal of Clinical Sleep Medicine found that adults with fibromyalgia had a much higher prevalence and risk of restless legs syndrome than healthy controls. The study suggests that treating RLS may improve sleep and quality of life in people with fibromyalgia. Results show that the prevalence of restless legs syndrome was about 10 times higher in the fibromyalgia...

2010-09-09 07:00:00

BURLINGTON, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, although increased uptake of currently-available therapies will drive modest $400 million growth in the Parkinson's disease drug market through 2019, generic erosion of key agents will constrain overall market growth in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010...

2010-07-26 15:15:00

SOUTH SAN FRANCISCO, Calif., July 26 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that the National Institutes of Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an...

2010-07-13 16:04:37

New animal research demonstrates diet-induced changes in brain chemical release Research to be presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, finds that prolonged exposure to a high fat diet is correlated with changes in the brain chemical dopamine within the striatum, a critical component of the brain's reward system.  The authors measured...

2010-03-31 07:00:00

NASHVILLE, Tenn. and GLEN ROCK, N.J., March 31 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year. According to the new Formulary Forum report entitled Formulary Advantages in Parkinson's Disease: Which...

2010-03-23 08:36:00

RIDGEFIELD, Conn., March 23 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease (PD), which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure....


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related